Next Investors logo grey

This year’s flu season sprang early – and with force

Published 21-JUN-2017 09:33 A.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Contrary to the traditional idea that a rock-solid work ethic means a willingness to work through all manner of maladies, showing up to the office when you’re unwell (and potentially contagious) isn’t so much a play for conscientious productivity as it is a gateway to delayed recovery and further infection.

A 2016 report prepared for Pathology Awareness Australia (PAA) by the Centre for International Economics which looks at improving the use of health resources quantifies the cost to the Australian economy associated with “presenteeism” at $34.1 billion per annum. This is equivalent to a productivity loss of 2.6% and a gross domestic product loss of 2.7%.

The good news? This year, for the first time, community pharmacies across Australia are able to administer a flu shot, in addition to medical centres and GPs. You can use the Vaccine Finder to locate a service near you.

The vaccine is recommended for anyone over six months of age, and is free under the National Immunisation Program for people perceived to be at higher risk from influenza and its complications.

Many employers also adopt a workplace flu vaccination program, providing a number of key benefits that work on a dual level — including the general health of businesses themselves.

It’s no secret workplaces are rife with sick leave and unplanned absences during flu season. But on the flipside, unwell employees who drag themselves to work — the aforementioned “presenteeism” (as opposed to absenteeism) — cost businesses through lost productivity, at the same time running the risk of infecting their colleagues.

But it’s just the flu, right?

With June marking not just the cautioning road-bump of mid-year (and the approach of a new financial year), but also the onslaught of another bitterly cold winter, all signs point to flu season.

This year, in Australia, flu season has actually sprung early, and with more force than it did last year. You can tell the season is upon is when public transport commutes start to resound with choruses of coughing and sneezing, and offices teem with employees who probably should be getting bedrest at home instead.

Health Department figures show that so far this year, almost 7,000 influenza cases have already been diagnosed in Australia — an increase of about 1,000 since the same period in 2016.

Each year, between 5% and 20% of the Australian population are likely to be infected with the influenza virus – and it’s estimated to cause between 1500 and 3,500 deaths, 18,000 hospitalisations, and 300,000 GP consultations per year in Australia.

The majority of cases aren’t fatal, but it can be a serious illness for certain population groups including the elderly, young children, pregnant women, or those with compromised immunity.

The flu versus the common cold

While the word “flu” tends to be used to refer to any generic combination of cold-like symptoms (or gastrointestinal illness, as with “stomach flu”), it’s important to note that there’s actually a marked difference between the common cold and the influenza virus.

Influenza is a highly contagious illness caused by a group of viruses that infect the respiratory tract. Unlike a cold, symptoms such as fever, sore throat and muscle aches develop suddenly with flu and last about a week. Generally, it produces a more severe illness than most other common viral respiratory infections. In some cases, severe illness and complications such as pneumonia and bronchitis can develop, and it can also worsen some pre-existing medical conditions.

Prevention is better than cure

The most effective form of prevention from influenza is still a yearly jab. While vaccine effectiveness can vary, in Australian studies, it’s estimated that the risk of influenza is reduced by about 40-50% in people who receive the vaccine.

The gamut of strains used in seasonal influenza vaccines can vary from year to year, depending on which viruses research indicates will be most common during the upcoming season. For instance, one of the four strains in the 2017 vaccine is called A/H3N2/Hong Kong/4801/2014, which refers to an influenza A type, a H3N2 subtype (flu viruses are defined and named by proteins on their surface, haemagglutinin – H, and neuraminidase – N), and a strain first isolated in Hong Kong in 2014.

Essentially, the vaccine causes antibodies to develop in the body about two weeks after vaccination. These antibodies provide protection against infection with the viruses that are in the vaccine.

Health professionals strongly recommend getting a new flu vaccine every year for a couple of reasons. Firstly, the body’s immune response from vaccination declines over time, so an annual vaccine is needed for maximum protection. Secondly, because influenza viruses are constantly in flux, the vaccine formulation is reviewed each year and updated accordingly to keep up with ever-changing flu viruses.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.